Certain medications commonly used to treat asthma and COPD can damage the environment and worsen respiratory issues. KYW medical editor Dr. Brian McDonough has more.

Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions.

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers ... the device directly to patients with asthma and COPD under a 510(k) over-the-counter ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

In Chicago public schools that adopted a stock inhaler program, more students who used a stock inhaler for asthma symptoms ...

In today’s fast-paced world, respiratory health has become a significant concern for many individuals. Conditions such as ...

2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Many Part D prescription drug plans cover Trelegy Ellipta, but costs can vary by plan type and insurer. Read more.